Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Multiple Myeloma × Immunoconjugates × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rectal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Stomach Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Colonic Neoplasms 1

Interventions

Dexamethasone 261 Bortezomib 144 Lenalidomide 115 pomalidomide 90 daratumumab 82 carfilzomib 59 Cyclophosphamide 38 Calcium Dobesilate 33 belantamab mafodotin 27 fludarabine 26 elotuzumab 23 Melphalan 21 ixazomib 20 isatuximab 20 venetoclax 15 selinexor 15 Prednisone 15 talquetamab 13 Panobinostat 13 plerixafor 11 Granulocyte Colony-Stimulating Factor 11 idecabtagene vicleucel 10 Zoledronic Acid 10 Thalidomide 10 Injections 10 pembrolizumab 9 nirogacestat 9 Methylprednisolone 9 Azacitidine 9 iberdomide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03489525 2022-03-28

MEDI2228

MedImmune LLC

Phase 1 Completed

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡